Merck & Co. said it is buying ArQule Inc. for about $2.7 billion, adding to its portfolio of cancer treatments beyond the company’s top-selling immunotherapy drug Keytruda. The purchase price, at $20 a share in cash, is more than double Friday’s closing price of $9.66 for ArQule, a Burlington, Mass., biopharmaceutical company.
As we near the end of 2019, it is time for us to look ahead and share what we believe 2020 has in store for the health care ecosystem. But first, let’s look back and assess how we did with our 2019 predictions.
Americans are more divided than ever, but if there’s one thing we share it is worry about the health of our families and how to pay for health problems that may arise. More than half of us (57 percent) have employer-provided insurance, and it’s one of the top reasons we value our jobs.
After training for more than ten years to be an orthopedic surgeon at institutions such as Stanford University and Mount Sinai in New York, Justin Saliman, MD, traded in his scalpel and scrubs for a life of instability and unpredictability by founding Ceterix Orthopedics.
Medicaid spending is threatening New York’s ability to close future state budget gaps in the coming years, making for an “Achilles heal” for its finances, Moody’s on Tuesday reported. New York’s budget gap for the coming year stands at $6.1 billion, with much of that fueled by overspending in the state’s Medicaid program, the costliest in the country.
A bankruptcy judge approved millions of dollars in bonus and incentive payments for a group of employees of OxyContin maker Purdue Pharma LP. But Judge Robert Drain put off a decision to approve a $1.3 million bonus for Purdue Chief Executive Officer Craig Landau at a hearing Wednesday in U.S. Bankruptcy Court in White Plains, N.Y.